Study type: Human research · Status: Verified against declared source

Cerebrolysin as an adjuvant therapy after mechanical thrombectomy in large vessel occlusion cardioembolic stroke: a propensity score matching analysis

2025

Study scale: Acute ischemic stroke (AIS) is a significant global health concern, given its high morbidity and mortality rates worldwide (1).

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Cardioembolic stroke, defined according to the TOAST criteria (25), has a higher bleeding risk (26).

Methods

Research in the field of cerebroprotection and neurorecovery in stroke has yielded encouraging results in both preclinical and clinical settings.

Scale or participants

Acute ischemic stroke (AIS) is a significant global health concern, given its high morbidity and mortality rates worldwide (1).

Key findings

The overall results demonstrated that patients treated with Cerebrolysin exhibited a significantly higher proportion of mRS scores of 0–2 at day 90 (64% vs.

Limitations and uncertainty

Endovascular recanalization therapy has demonstrated considerable efficacy in the treatment of acute ischemic stroke (AIS).

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.